Irene
Gañan Gomez
Investigadora
Argitalpenak (42) Irene Gañan Gomez argitalpenak
2024
-
Accurate identification of locally aneuploid cells by incorporating cytogenetic information in single cell data analysis
Scientific Reports, Vol. 14, Núm. 1
-
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Clinical Cancer Research, Vol. 30, Núm. 7, pp. 1319-1326
-
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes
Nature Communications, Vol. 15, Núm. 1
-
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma
Nature Communications, Vol. 15, Núm. 1
-
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
Cell Reports Medicine, Vol. 5, Núm. 6
2022
-
A machine learning-based method for automatically identifying novel cells in annotating single-cell RNA-seq data
Bioinformatics, Vol. 38, Núm. 21, pp. 4885-4892
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)
Nature Medicine
-
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
The Lancet Haematology, Vol. 9, Núm. 10, pp. e756-e765
-
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia
Leukemia, Vol. 36, Núm. 8, pp. 2097-2107
-
Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
STAR PROTOCOLS, Vol. 3, Núm. 4
-
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia
Leukemia and Lymphoma, Vol. 63, Núm. 13, pp. 3154-3164
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Nature Medicine, Vol. 28, Núm. 3, pp. 557-567
-
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
BLOOD CANCER DISCOVERY, Vol. 3, Núm. 6
-
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Experimental Hematology, Vol. 115, pp. 44-53
2021
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
Blood Cancer Journal
-
Hematopoiesis under telomere attrition at the single-cell resolution
Nature Communications, Vol. 12, Núm. 1
-
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia
Leukemia Research, Vol. 101
2020
-
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents
Leukemia and Lymphoma, Vol. 61, Núm. 6, pp. 1493-1499
-
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
Leukemia, Vol. 34, Núm. 3, pp. 872-881
2019
-
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
Blood Advances, Vol. 3, Núm. 6, pp. 922-933